Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 190.10
Change Today -4.70 / -2.41%
Volume 247.3K
As of 9:24 AM 05/3/15 All times are local (Market data is delayed by at least 15 minutes).

itamar medical ltd (ITMR) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/25/14 - $242.00
52 Week Low
10/13/14 - $148.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ITAMAR MEDICAL LTD (ITMR)

Related News

No related news articles were found.

itamar medical ltd (ITMR) Related Businessweek News

No Related Businessweek News Found

itamar medical ltd (ITMR) Details

Itamar Medical Ltd. develops, markets, and sells diagnostic medical devices. Its medical devices are based on Peripheral Arterial Tone (PAT) signal, a non-invasive window to the cardiovascular system and the autonomic nervous system. The company offers EndoPAT, a medical device for noninvasive endothelial function assessment used in preeminent clinical and research institutions, epidemiological population based studies (such as Framingham Heart Study), and pharmaceutical clinical phase studies; WatchPAT, a medical-grade sleep test for the diagnoses of obstructive sleep apnea, a condition common in metabolic and cardiovascular disease. It also provides companion diagnostic products to support drug discovery and development from inception straight through to regulatory approval and launch. The company was founded in 1997 and is based in Caesarea, Israel.

Founded in 1997

itamar medical ltd (ITMR) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: 558.0K
Compensation as of Fiscal Year 2013.

itamar medical ltd (ITMR) Key Developments

Itamar Medical Inc. and Arterial Health International Sign Representation Agreement

Itamar Medical Inc. and Arterial Health International LLC (AHI) announced they have signed last month a representation agreement. Under the terms of the agreement, AHI will be Itamar's exclusive cardiovascular diagnostic testing service representative and will market both EndoPAT and WatchPAT to physicians in ten states in the US. AHI will continue to offer EndoPAT testing as a key component of the cardiovascular diagnostic test package it offers to primary care physicians and their patients. In addition, WatchPAT testing will also be added as a part of AHI's suite of services. As part of the three-year agreement, AHI is also committed to an annual minimum purchase requirement of EndoPAT and WatchPAT devices and accessories from Itamar Medical. The EndoPAT, manufactured by Itamar Medical, is a device used to test the functioning of the endothelial layer that regulates arterial function. It is the only FDA-cleared device intended for assessing endothelial function, diagnosing coronary artery disease risk and other cardiovascular diseases.

Itamar Medical Ltd. Presents at BIO-Europe Spring 2015, Mar-09-2015

Itamar Medical Ltd. Presents at BIO-Europe Spring 2015, Mar-09-2015 . Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.

Galmed Pharmaceuticals Ltd. Announces Purchase of 60 EndoPAT Devices and Accessories From, and Collaboration With, Itamar Medical Ltd

Galmed Pharmaceuticals Ltd. announced the purchase of 60 EndoPAT devices and accessories from, and collaboration with, Itamar Medical Ltd. to include an assessment of endothelial, or arterial, function in the company's planned Phase IIb clinical trial of its drug candidate, aramchol, in Non-Alcoholic Steato-Hepatitis patients suffering from obesity and insulin resistance. The purchase price for the EndoPAT devices and accessories was approximately $750,000 and was contemplated in the company's use of proceeds with respect to such Phase IIb trial. The collaboration with Itamar Medical will allow Galmed to further its understanding of aramchol's effect on endothelial function, which may be impaired in NASH patients. In aramchol's prior Phase IIa clinical trial, it observed a dose-dependent non-statistically significant improvement in endothelial function, which suggests a positive effect of the drug on early stage atherosclerosis, or hardening of the arteries, in addition to a significant reduction in liver fat content. If its planned Phase IIb trial confirms aramchol's effect on endothelial function in NASH patients, it believes that EndoPAT could potentially be used by physicians in out-patient clinics as a non-invasive test for aramchol's effect on vascular function.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ITMR:IT 190.10 -4.70

ITMR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ITMR.
View Industry Companies

Industry Analysis


Industry Average

Valuation ITMR Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ITAMAR MEDICAL LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at